<DOC>
	<DOCNO>NCT00832637</DOCNO>
	<brief_summary>This single arm phase II trial Gemcitabine Oxaliplatin ( Gem-Ox ) Erlotinib ( Tarceva ) treatment hepatocellular carcinoma ( HCC ) biliary tree cancer ( BTC ) patient platelet count 100,000/ÂµL . The purpose study determine tumor control rate follow treatment GEM-OX combine Tarceva patient HCC . Tumor control rate define percentage patient achieve complete response , partial response , stable disease 24 week follow treatment .</brief_summary>
	<brief_title>Gemcitabine , Oxaliplatin , Tarceva &amp; /or Cisplatin HCC &amp; Biliary Tree Cancers</brief_title>
	<detailed_description>The incidence mortality HCC increase United States . Promising response observe HCC patient treat gemcitabine cisplatin , inclusing good disease stabilization progression free survival . Cisplatin-gemcitabine enhances cytotoxicity cisplatin increase formation cytotoxic platinum DNA adduct . Similarly , Oxaliplatin also DNA cross linkage property one could assume combination gemcitabine likely potentiate cytotoxicity latter . Erlotinib also report result clinical benefit HCC BTC patient . Based prior finding , embark phase II protocol gemcitabine , oxaliplatin , erlotinib HCC BTC patient .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Histologically cytologically confirm hepatocellular carcinoma ( HCC ) biliary tree cancer ( BTC : : intra extrahepatic cholanciocarcinoma , bile duct cancer , adenocarcinoma Ampulla Vater and/or gallbladder carcinoma ) . Patients must measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) . Age 18 year old . Eastern Cooperative Oncology Group ( ECOG ) Performance Score 02 Adequate bone marrow evidence : Absolute neutrophil count ( ANC ) &gt; 1,500/L . Platelet count &gt; 100,000/L . Absence regular red blood cell transfusion requirement . Adequate renal function evidence serum creatinine &lt; 1.5 mg/dL . Adequate hepatic function evidence : Serum total bilirubin 1.5x Upper Limit Normal ( ULN ) . Alkaline phosphatase &lt; 3x ULN reference lab ( &lt; 5x ULN patient know hepatic metastasis ) . Serum glutamicoxaloacetic transaminase ( SGOT ) / serum glutamicpyruvic transaminase ( SGPT ) &lt; 3x ULN reference lab ( &lt; 5x ULN patient know hepatic metastasis ) . Patients must life expectancy 12 week . Patients must recover acute late effect prior surgery , radiotherapy antineoplastic therapy . Patients childbearing potential agree use effective form contraception study 90 day follow last dose study medication ( effective form contraception oral contraceptive double barrier method ) . A patient may enrol trial follow criterion meet : Patients active infection fever &gt; 38.50 degree Celcius within 3 day first schedule day protocol treatment . Patients active central nervous system ( CNS ) metastasis . Patients stable CNS disease , undergone radiotherapy least 4 week prior plan first protocol treatment stable dose corticosteroid 3 week eligible trial . History prior malignancy within past 5 year except curatively treat basal cell carcinoma skin , cervical intraepithelial neoplasia , localized prostate cancer current prostate serum antigen ( PSA ) &lt; 1.0 mg/dL 2 successive evaluation least 3 month apart , recent evaluation within 4 week entry . Patients prior treatment know hypersensitivity component oxaliplatin gemcitabine . Patients receive chemotherapy within 30 day first schedule day protocol treatment . Patients receive radiotherapy 25 % bone marrow ; patient receive radiotherapy within 4 week entry . Patients receive concurrent investigational therapy receive investigational therapy within 30 day first schedule day protocol treatment ( investigational therapy define treatment currently regulatory authority approve indication ) . Peripheral neuropathy Grade 2 . Patients pregnant lactate . Patients life expectancy le 12 week . Any medical condition , include mental illness substance abuse , deem Investigator , likely interfere patient 's ability sign inform consent , cooperate participate study , interfere interpretation result . Patients follow laboratory parameter : Abnormal hematological value ANC &lt; 1500/mm3 , thrombocytopenia &lt; 99,000 . Impaired renal function serum creatinine &gt; 1.5x ULN . Serum bilirubin &gt; 1.5xULN . Albumin &lt; 2.5 mg/dl . Unwillingness participate inability comply protocol duration study . History allogeneic transplant . Known human immunodeficiency virus ( HIV ) . Clinically significant heart disease define New York Heart Association ( NYHA ) class 3 4 heart disease . Known exist uncontrolled coagulopathy . Patients severe medical problem uncontrolled diabetes chronically debilitate disease investigator feel might compromise study participant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Liver</keyword>
	<keyword>Gallbladder</keyword>
	<keyword>Bile duct</keyword>
	<keyword>Gemzar</keyword>
	<keyword>Eloxatin</keyword>
	<keyword>Tarceva</keyword>
	<keyword>erlotinib</keyword>
	<keyword>Gem-ox</keyword>
</DOC>